Doximity is trading at $23.90, down -4.17%, after no clear company-specific catalyst emerged in overnight coverage.

  • Latest earnings were reported August 6, with revenue beating expectations but adjusted EPS missing estimates
  • August 18 coverage noted a director’s previously planned share sale, not a new transaction
  • Broader risk sentiment remains fragile ahead of the FOMC minutes, while pre-market indexes are modestly higher.